Disclosure Statement of Financial Interest I currently have, or have - - PowerPoint PPT Presentation

▶

Nov 05, 2023 140 likes •400 views

Disclosure Statement of Financial Interest I currently have, or have had over the last two years, an affiliation or financial interests or interests of any order with a company or I receive compensation or fees or research grants with a commercial

SLIDE 1

☑ Je déclare les liens d'intérêt potentiel suivants : Subvention : GE Healthcare, Novartis, BMS-Pfizer, Abbot Speaker's name : Erwan, Donal, Rennes

Disclosure Statement of Financial Interest

I currently have, or have had over the last two years, an affiliation or financial interests or interests of any order with a company

r I receive compensation or fees or research grants with a commercial company :

Speaker's name : Gilles, Barone-Rochette, Grenoble ☑ Je ne déclare pas de les liens d'intérêt potentiel

SLIDE 2

L'essentiel de 2018

CARDIO-VASCULAR IMAGING

Pr DONAL Erwan

Rennes University Hospital and LTSI, INSERM1099 RENNES, France erwan.donal@chu-rennes.fr

Pr BARONE-ROCHETTE Gilles

CHU-GA, and LRB INSERM1039 GRENOBLE, France GBarone@chu-grenoble.fr

SLIDE 3

Best clinical care will need an appropriate use of one or more imaging modalities.

SLIDE 4

JAMA Cardiol. 2017;2(3):285-292.

2118 patients (mean [SD] age, 47 [18] years; 1525 [72.0%] male), 1881 (88.8%) had BAV with fusion raphe, whereas 237 (11.2%) had BAV without raphe

SLIDE 5

SLIDE 6

High native T1 value on noncontrast T1 mapping CMRis a novel, independent predictor of adverse outcome in patients with significant AS.

J AmColl Cardiol Img 2018;11:974–83

SLIDE 7

SLIDE 8

J Am Coll Cardiol 2018;72:823–34

356 primary MR patients

MVP patients with LV fibrosis had the highest event rate for arrhythmic events.

SLIDE 9

J Am Coll Cardiol Img 2018;11:872–901

SLIDE 10

SLIDE 11

Will Artificial Intelligence Replace the Human Echocardiographer?

Clinical Considerations

Circulation. 2018;138:1639–1642.

SLIDE 12

Using 14 035 echocardiograms spanning a 10-year period

SLIDE 13

SLIDE 14

J Am Heart Assoc. 2018;7:e009362. DOI: 10.1161/JAHA.118.009362

Lack of a Tricuspid Regurgitation Doppler Signal and Pulmonary Hypertension by Invasive Measurement

SLIDE 15

SCOT-HEART investigators. NEJM 2018

CT: SCOT-HEART

2015 2018 P = 0.004

More Antiplatelet therapy 40 vs 50% Statin 50 vs 59 % Beta-blocker 28 vs 35 %

SLIDE 16

CT: CT-FFR and CAD management

Fairbairn et al. EHJ 2018; 39: 3701–3711

5083 patients, 38 international sites from 15 July 2015 to 20 October 2017 CTA and CT-FFR 3,674 patients, single-center observational from May 2014 and December 2016, CTA and CT-FFR

Nørgaard et al. JACC.2018;72:2123–34

The endpoint : all-cause death, MI, hospitalization for unstable angina, and unplanned coronary revascularization

SLIDE 17

CT: new image of instable coronary plaque

Oikonomou et al. Lancet 2018; 392: 929–39

Coronary artery inflammation inhibits adipogenesis in adjacent perivascular fat A novel imaging biomarker—the perivascular fat attenuation index (FAI) 1872 participants in the derivation cohort / 2040 patients in the validation cohort End-point: all-cause and cardiac mortality

HRs adjusted for age, sex, hypertension, hypercholesterolaemia, diabetes mellitus, smoking status, epicardial adipose tissue volume, extent of coronary artery disease (Duke coronary artery disease index), number of high-risk plaque features, and tube voltage.

SLIDE 18

CMR: Coronary microvascular disease

Stress Without Gadolinium 𝚬 T1 values were defined as: ([stress T1 rest T1] / rest T1 * 100)

Liu et al. JACC 2018;71:957–68

SLIDE 19

True positive: obstructive coronary arteries (FFR <0.8)

Liu et al. JACC 2018;71:957–68

CMR: Coronary microvascular disease

SLIDE 20

CMR: Myocarditis new expert Recommendation

Ferreira et al. JACC 2018;72:3158–76

SLIDE 21

CMR: Cardiac Amyloidosis T2 mapping

Kotecha et al. JACC 2018;71:2919–31

100 AL amyloidosis, 186 with cardiac ATTR amyloidosis,, and 30 healthy volunteers

SLIDE 22

Nuclear medicine: Instable plaque coronary

Lee et al. Circ Cardiovasc Imaging. 2018;10:e006704

51 prospectively enrolled patients (93 stenoses) PET CT/ PET IVUS OCT

SLIDE 23

Nuclear medicine: Cardiac sarcoidosis

Wicks et al. EHJ- CI 2018; 19: 757–767 Sperry et al. J Am Coll Cardiol Img 2018;11:336–45

51 suspected CS PET/MR endpoint : death, aborted sudden cardiac death, sustained ventricular arrhythmia, complete heart block, and hospital admission with decompensated heart failure. adjusted for age, sex, and LVEF Multivariable Cox models for death, heart transplant,

ventricular arrhythmia requiring defibrillation With 203 patients evaluated by PET

SLIDE 24

FILIALE D’IMAGERIE CARDIOVASCULAIRE de la SFC

Développer l’enseignement Recommandations Soutenir la recherche clinique Formation initiale Formation continue Expertise auprès des patients

www.echowebline.com

Webcasts Articles scientifiques Interviews Cas cliniques Vignettes DPC & cours en ligne Recommandations

Echocardiographie et Imagerie de coupes

SLIDE 25

The large number of studies and patients in this meta-analysis demonstrate clear findings that SMR may be a marker of adverse

utcomes independent of how it has been detected or graded.

However, because SMR is an intrinsic consequence of LV- dysfunction, causality between SMR and mortality should not be implied

JAMA Cardiol. 2017;2(10):1130-1139